Amgen Boosts Bid for Onyx to $130 a Share

Aug. 7 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Cristina Alesci reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

Was the DNC Hack Preventable?
56:35 - Eric O'Neill, Carbon Black's national security strategist, discusses how to respond to government hacks with Bloomberg's Emily Chang on "Bloomberg West." (Source: Bloomberg)
  • Will Berlin Become Europe's Top Tech Hub?
  • Full Show: Best of Bloomberg Markets Middle East (07/29)
  • Talend CEO: Why We Decided to Go Public Now